Pharmaceutical News

RSS

RapidChek- SELECT Salmonella highly sensitive to the presence of S. Typhi vaccine in stool

Salmonella Typhi (S. Typhi) is the causative agent of typhoid fever, a serious health threat resulting in some 22 million new cases yearly and approximately 217,000 fatalities. A number of novel vaccine candidates using live attenuated strains of Salmonella are being developed, but care must be taken to ensure the bacteria are not excreted into the environment following vaccination.

29 Jun 2012

Boston College chemists use nanowires to power photosynthesis

Harnessing the power of the sun has inspired scientists and engineers to look for ways to turn sunlight into clean energy to heat houses, fuel factories and power devices. While a majority of this research focuses on energy production, some researchers are looking at the potential uses of these novel solar technologies in other areas.

29 Jun 2012

AASLD, EASL to hold special conference on therapy of HCV

The European Association for the Study of the Liver (EASL), together with the American Association for the Study of Liver Diseases (AASLD), will be holding an exciting "Special Conference" dedicated to the timely topic of: Therapy of Hepatitis C: Clinical Application and Drug Development.

29 Jun 2012

Astellas Pharma receives FDA approval for Myrbetriq to treat overactive bladder

The U.S. Food and Drug Administration today approved Myrbetriq (mirabegron) to treat adults with overactive bladder, a condition in which the bladder muscle cannot be controlled, squeezes too often or squeezes without warning.

29 Jun 2012

Millennium introduces novel pharmacogenetic testing

Millennium Laboratories, the leading research-based clinical diagnostic company dedicated to improving the lives of people suffering from pain, announced today the introduction of Millennium Pharmacogenetic Testing.

29 Jun 2012

Bayer receives priority review designation from FDA for regorafenib NDA

Bayer HealthCare and Onyx Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has granted priority review designation to Bayer HealthCare's New Drug Application (NDA) filed end of April 2012 for the oral multi-kinase inhibitor regorafenib, for the treatment of patients with metastatic colorectal cancer (mCRC) whose disease has progressed after approved standard therapies.

29 Jun 2012

Gilead submits cobicistat NDA with FDA for treatment of HIV

Gilead Sciences, Inc. announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of cobicistat, a pharmacoenhancing or "boosting" agent that increases blood levels of certain commercially available protease inhibitors, including atazanavir and darunavir, in order to enable once-daily dosing.

29 Jun 2012

AHF urges Gilead to set initial price on latest HIV/AIDS drug combination

AIDS Healthcare Foundation (AHF) announced that California State Treasurer Bill Lockyer has sent a letter to California-based drug company, Gilead Sciences, Inc. urging the company to set an initial price on its latest HIV/AIDS drug combination—which is known as the 'Quad'—that is "…sensitive to ongoing state budget difficulties," and which will also "…provide the means to keep people with HIV/AIDS alive and as healthy as possible."

28 Jun 2012

UTMB researchers improve existing experimental vaccine for Rift Valley fever virus

University of Texas Medical Branch researchers have significantly improved an existing experimental vaccine for Rift Valley fever virus, making possible the development of a more effective defense against the dangerous mosquito-borne pathogen.

28 Jun 2012

Efforts to fight illegal drugs contributing to spread of HIV, report says

The Global Commission on Drug Policy (GCDP) on Tuesday published a report titled "The War on Drugs and HIV/AIDS: How the Criminalization of Drug Use Fuels the Global Pandemic," which "condemns the drug war as a failure and recommends immediate, major reforms of the global drug prohibition regime to halt the spread of HIV infection and other drug war harms," according to the report summary.

28 Jun 2012

Intensive early treatment slows down progression of type 2 diabetes

Intensive early treatment of type 2 diabetes slows down progression of the disease by preserving the body's insulin-producing capacity, a UT Southwestern study has shown.

28 Jun 2012

Arena receives FDA approval for Belviq to treat obesity

The U.S. Food and Drug Administration today approved Belviq (lorcaserin hydrochloride), as an addition to a reduced-calorie diet and exercise, for chronic weight management.

28 Jun 2012

Touch important for side-effects of medicines for premature babies with respiratory problems

Discovering that touch is important for the side-effects of a medicine for premature babies with respiratory problems. This is what Sanne Claessens finds so fascinating about fundamental research in medical pharmacology. PhD defence 27 June.

28 Jun 2012

Phototron launches new SG Sensors-brand sensors and controllers, growers

Phototron Holdings, Inc., a leading technology supplier to the hydroponic growing industry, today announced that its wholly owned SG Sensors division launched beta testing for its state-of-the-art wireless sensors and controllers, designed for growers of all sizes in the medicinal marijuana industry.

28 Jun 2012

Data from Infinity’s IPI-145 pre-clinical study on inflammatory diseases

Infinity Pharmaceuticals, Inc. today reported preclinical data for IPI-145, the company's oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma. The data demonstrate potent PI3K-delta and -gamma inhibition in biochemical, cellular and whole blood assays and activity in multiple preclinical models of inflammatory disease, including rheumatoid arthritis and asthma.

28 Jun 2012

OCC members praise FDA approval of new obesity drug – Belviq

Today, members of the Obesity Care Continuum (OCC) applauded the Food and Drug Administration's (FDA) approval of a new obesity drug – Belviq (lorcaserin HCl). Belviq is the first obesity drug to be approved in the past 13 years.

28 Jun 2012

Powerful new technique can manipulate the building-block molecules of organic chemistry

Scientists at The Scripps Research Institute have developed a powerful new technique for manipulating the building-block molecules of organic chemistry. The technique enables chemists to add new functional molecules to previously hard-to-reach positions on existing compounds-making it easier for them to generate new drugs and other organic chemicals.

28 Jun 2012

New compound could treat certain types of genetic disorders in muscles

Scientists at UCLA have identified a new compound that could treat certain types of genetic disorders in muscles. It is a big first step in what they hope will lead to human clinical trials for Duchenne muscular dystrophy.

28 Jun 2012

Gilead submits elvitegravir NDA with FDA for treatment of HIV-1 infection

Gilead Sciences, Inc. announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of elvitegravir, an integrase inhibitor for the treatment of HIV-1 infection in treatment-experienced adults.

28 Jun 2012

Humanetics receives U.S. patent for NIC5-15 to treat Alzheimer's

The US Patent and Trademark Office has issued a patent supporting a long-term, multi-year research and development collaboration between Mount Sinai School of Medicine (MSSM) and Humanetics Corporation to develop and commercialize a safe and effective means to prevent or slow the progression of Alzheimer's disease. Humanetics is the exclusive licensee for this patent.

28 Jun 2012